Figure 1.

Rational design of OmpAVac. (A) Schematic representation of OmpA (upper) and OmpAVac (lower). (B) Reactions of loop1, loop2, loop3 and loop4 of OmpA with sera from E. coli K1-infected patients. The optical density (OD) from ELISAs of each patient donor and the average of 10 health donors was shown. (C) Evaluation of the immunogenicity of loop1, loop2, loop3, and loop4 in the form of OmpA_TM (transmembrane domain of OmpA) fused with MBP (maltose binding protein) tag. The titers of anti-loop1, anti-loop2, anti-loop3, and anti-loop4 antibodies from MBP-OmpA_TM-immunized mice are shown. (D) Evaluation of the immunogenicity of loop1, loop2, loop3, and loop4 in the form of synthesized peptides. Mice were immunized with synthesized peptides encoding loop1, loop2, loop3, or loop4 of OmpA. The titers of the anti-loop1, anti-loop2, anti-loop3, and anti-loop4 antibodies are shown. The significance of the differences was determined by unpaired parametric tests (Student's t-test for two groups or one-way ANOVA for three or more groups). ^*indicates a significant difference when P-value is below 0.05, while “n.s.” indicates no significant difference.